| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
FT-671 targets ubiquitin-specific protease 7 (USP7). USP7 is a deubiquitinating enzyme that removes ubiquitin from target proteins, thereby regulating their stability and function. By inhibiting USP7, FT-671 stabilizes the ubiquitination and degradation of its substrates, including MDM2. This leads to the stabilization of p53 and induction of p21, resulting in cell cycle arrest and apoptosis.
|
|---|---|
| ln Vitro |
In vitro, FT-671 is a potent USP7 inhibitor, with an IC50 of 52 nM and a Kd of 65 nM. It blocks the proliferation of MM.1S cells with an IC50 of 33 nM. It has high affinity and specificity for USP7. Its effects on USP7 substrates have been characterized.
|
| ln Vivo |
In vivo, FT-671 is orally available. It suppresses tumor growth in mice. It has been shown to inhibit tumor growth in xenograft models. Its ability to inhibit USP7 and stabilize p53 contributes to its antitumor efficacy.
|
| Enzyme Assay |
In vitro enzyme assays for FT-671 measure its inhibition of USP7 activity. The compound is incubated with USP7 and a fluorogenic ubiquitin substrate. The cleavage of the substrate is monitored fluorometrically. The IC50 and Kd values are determined.
|
| Cell Assay |
In vitro cell-based assays for FT-671 involve treating cancer cell lines (e.g., MM.1S) with the compound and measuring cell viability (e.g., MTT assay). Its effects on USP7 activity and the stabilization of p53 are assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for FT-671 have been conducted in mouse xenograft models. Tumor-bearing mice are treated with FT-671 orally, and tumor growth inhibition is monitored. Its effects on USP7 activity and p53 levels in tumor tissues are assessed.
|
| ADME/Pharmacokinetics |
FT-671 has a molecular weight of 533.49 and a molecular formula of C24H23F4N7O3. It is soluble in DMSO. Its purity is >98%. It is typically stored under recommended conditions for research compounds.
|
| Toxicity/Toxicokinetics |
FT-671 is for research use only and is not intended for human use. Its safety profile is being evaluated in preclinical studies. As a potent USP7 inhibitor, its toxicity is related to its mechanism of action. Standard safety precautions should be taken when handling.
|
| References | |
| Additional Infomation |
FT-671 is a potent, non-covalent, and selective USP7 inhibitor. It has an IC50 of 52 nM and a Kd of 65 nM. It blocks MM.1S cell proliferation (IC50 = 33 nM). It suppresses tumor growth in mice and is orally available. It is being developed as an anticancer agent.
|
| Molecular Formula |
C24H23F4N7O3
|
|---|---|
| Molecular Weight |
533.478138208389
|
| Exact Mass |
533.18
|
| Elemental Analysis |
C, 54.03; H, 4.35; F, 14.24; N, 18.38; O, 9.00
|
| CAS # |
1959551-26-8
|
| Related CAS # |
1959551-27-9 (R-isomer);1959551-26-8;
|
| PubChem CID |
121457027
|
| Appearance |
Solid powder
|
| LogP |
1.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
38
|
| Complexity |
898
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CN(CCC1(CN2C=NC3=C(C2=O)C=NN3C4=CC=C(C=C4)F)O)C(=O)C[C@@H](C(F)F)N5C=CC(=N5)F
|
| InChi Key |
BLSNYSFLZAWBIV-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C24H23F4N7O3/c25-15-1-3-16(4-2-15)35-22-17(12-30-35)23(37)33(14-29-22)13-24(38)6-9-32(10-7-24)20(36)11-18(21(27)28)34-8-5-19(26)31-34/h1-5,8,12,14,18,21,38H,6-7,9-11,13H2/t18-/m0/s1
|
| Chemical Name |
5-[[1-[(3S)-4,4-difluoro-3-(3-fluoropyrazol-1-yl)butanoyl]-4-hydroxypiperidin-4-yl]methyl]-1-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-4-one
|
| Synonyms |
FT-671; FT671; FT 671
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8745 mL | 9.3724 mL | 18.7448 mL | |
| 5 mM | 0.3749 mL | 1.8745 mL | 3.7490 mL | |
| 10 mM | 0.1874 mL | 0.9372 mL | 1.8745 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA